Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma

SIMPLE SUMMARY: We investigated the prognosis of intermediate-stage hepatocellular carcinoma (HCC) patients who received lenvatinib (LEN) until unacceptable adverse events or progressive disease, followed by transcatheter arterial chemoembolization (TACE) on demand. The overall survival (OS) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mawatari, Seiichi, Tamai, Tsutomu, Kumagai, Kotaro, Saisyoji, Akiko, Muromachi, Kaori, Toyodome, Ai, Taniyama, Ohki, Sakae, Haruka, Ijuin, Sho, Tabu, Kazuaki, Oda, Kohei, Hiramine, Yasunari, Moriuchi, Akihiro, Sakurai, Kazuhiro, Kanmura, Shuji, Ido, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776720/
https://www.ncbi.nlm.nih.gov/pubmed/36551623
http://dx.doi.org/10.3390/cancers14246139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776720/
https://www.ncbi.nlm.nih.gov/pubmed/36551623
http://dx.doi.org/10.3390/cancers14246139

Ejemplares similares